Vanderbilt Ingram Cancer Center

After successfully leading Vanderbilt-Ingram Cancer Center (VICC) through years of growth in patient volumes and enhanced care options, Michael Neuss, MD, Chief Medical Officer of the VICC Clinical Enterprise, is retiring as CMO. Neuss will be succeeded by Madan Jagasia, MBBS, MSCI, MMHC, who has been named to the George and Beverly Rawlings Directorship and is section chief, Hematology and Stem Cell Transplant and director of the Outpatient Stem Cell Clinic.

For the 10th year in a row Vanderbilt University Medical Center (VUMC) and Vanderbilt-Ingram Cancer Center (VICC) have been named a CEO Cancer Gold Standard employer by the

Jordan Berlin, MD, has been named associate director of Clinical Investigation Strategy and Shared Resources at Vanderbilt-Ingram Cancer Center (VICC).

A team of investigators led by Fabien Maldonado, MD, associate professor of Medicine at Vanderbilt, and Tobias Peikert, MD, assistant professor of Medicine at Mayo Clinic, Rochester, Minnesota, has identified a new technology to address false positives in CT-based lung cancer screening. The study was published in the latest issue of PLOS One.

W. Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.

Two Vanderbilt students were honored for their stellar scientific research during the Vanderbilt-Ingram Cancer Center (VICC) Annual Scientific Retreat held May 3 at the Vanderbilt University Student Life Center.